IMPC-Industry Liaison Workshop
Welcome & Intro
Tom Weaver
Director, Mary Lyon Centre,
MRC Harwell
Wellcome Trust
London, 7th April 2011
Agenda & Discussion Sessions
IMPC Overview – Mark Moore, IMPC/NIH
Perspectives on Engagement Models – Before Lunch (12:45)
1. Large Pharma – Steve Harrison, GSK
2. Preferred Suppliers – Paul Rounding, Taconic
Perspectives on Engagement Models – After Lunch (1:30)
3. IMPC as Service Provider/CRO, Yann Herrault (ICS)
4. Database Support or Tool Developers, Abel Ureta-Vidal, Eagle
Genomics
Break for Tea/Coffee @ 3:30
Review Main Points & Wrap Up by 4-4:30
IMPC-Industry Liaison Workshop
IMPC & Industry - Context
National funding strategies demand collaboration
 Knowledge transfer and innovation (science, technology, applications to
create new markets and jobs)
 Basic research & focus on “Translation”
Vendors/Suppliers/Biotech provide academic researchers
with...
 Essential tools and platforms for creating and working with mouse
models
 Their support helps drive innovation
Pharma Biotech exploit mouse models for drug development
 Thirty-four of the top 100 drugs by sales volume (>$44B) in the US
were enabled by the use of a mouse models.
 There is a high degree of correlation between mode of action of drugs in
humans and the phenotypes of their corresponding targets in mice.
IMPC-Industry Liaison Workshop
Osteoporosis Drug “Prolia “
(Denosumab)
®
2% Stock
Rise
$2B
Value!
The discovery program began in an Amgen lab when researchers
observed that one of the knockout mice it had developed during
gene disabling research work had grown huge.
"We noticed, hey that's a really big mouse,"
Amgen CEO Kevin Sharer recently told the Wall Street Journal.
"It's really got big bones."
IMPC-Industry Liaison Workshop
IMPC & Industry - Challenge
IMPC NEEDS TO:
 Ensure that the output of the IMPC truly does benefit
biopharmaceutical research and development programs.
 Take into account the expert views, experiences and expectations
of industry researchers working with mouse models or providing
products, pre-clinical services, or enabling technology platforms.
IMPC-Industry Liaison Workshop
IMPC Governance & Management
11 Academic, Government Institutes












Steering Committee & Secretariat
MRC Harwell (Steve Brown, current Chair;
Tom Weaver)
Secretariat (Mark Moore, Executive Director;
Jorg Rossbacher)
MRC (Nathan Richardson, Clare Newland)
NIH (Jane Peterson, Eric Green, Jim Battey,
Colin Fletcher, Martin Guyer)
Sanger Institute (Alan Bradley, Karen
Kennedy)
Wellcome Trust (Michael Dunn, Clare
McVicker)
Infrafrontier (Martin Hrabe de Angelis)
Helmholtz Zentrum Munich (GMC) (Martin
Hrabe de Angelis)
Toronto Centre for Phenogenomics (TCP)
(Colin McKerlie)
Institute Clinique de la Souris (ICS)
(Yann Herault)
Australian Phenomics Network (Adrienne
McKenzie)
European Commission (Jacques Remacle,
observer)
IMPC-Industry Liaison Workshop
To Date, No Industry Partners
Engagement Essential
Strategy Needed
Set up Working Group
IMPC Industry Working Group
Allan Bradley, WTSI, Cambridge UK,
abradley@sanger.ac.uk
Martin Hrabe-deAngelis, GMC, Munich Germany,
hrabe@helmholtz-muenchen.de
Colin McKerlie, TCP, Toronto Canada,
colin.mckerlie@phenogenomics.ca
Mark Moore, NIH/IMPC, San Francisco USA,
mwmoore880@comcast.net
Tom Weaver (Chair), MRC Harwell, Oxford UK,
t.weaver@har.mrc.ac.uk
IMPC-Industry Liaison Workshop
IMPC Industry Working Group
Remit:
 The working group is tasked to developing a strategy for liaising
with Industry and making recommendations for consideration by
the IMPC steering committee.
Goals:
 How the IMPC can best serve the needs of the biopharmaceutical
industry.
 Communicate with industry about our program.
 Explore how industry can participate in the IMPC.
 Develop and implement an engagement plan.
IMPC-Industry Liaison Workshop
Planned Activities
Draft Engagement Plan
 Consider Different Models
 Begin Discussing with Industry
Contact List (>100 so far)
Workshop (London, April 7th)
Sign-off By Steering Committee
Launch @ Bio2011 (Washington DC, July 2011)
IMPC-Industry Liaison Workshop
Goals of London Workshop
 Value Add: How can the IMPC best serve the needs of the
biopharmaceutical industry and its product and service providers? What
can this academic consortium be providing to industry that they can’t or
are not willing to do themselves?
 Partnering: Gauge what interest BioPharma, Contract Research
Organizations, and platform vendors have for participating in the IMPC,
and propose one or several models for developing IMPC - Industry
partnerships.
 Contribution: What can industry offer the IMPC? Consider opportunities
for industry to contribute either funds or in kind resources such as
services, reagents, information, or technology to advance the program.
 Communication: What are the best ways to communicate with industry
about IMPC so that they are aware of this important research program and
access to data, technology, analysis tools, and mouse models.
IMPC-Industry Liaison Workshop
Outcome of Our Meeting
Consensus On:
 IMPC Value Proposition To Industry
 Realistic Engagement Model for Industrial Involvement
 Identify Barriers To Making This Happen
 How To Communicate & Attract Champions
Leading To Industry Engagement Strategy & Action Plan
IMPC-Industry Liaison Workshop
Thank You For Participating!
IMPC-Industry Liaison Workshop